Discover GSK's ASCI Science
Whether you are a patient, family member, close friend or just an interested reader, this website is dedicated to presenting you the GSK Biologicals novel approach to cancer treatment based on Antigen-Specific Cancer Immunotherapeutics or ASCI. ASCI are a novel class of medicines, currently being investigated in clinical trials, designed to educate the patient's own immune system to recognize and eliminate cancer cells in a highly specific manner.
Visit public websiteHealthcare professionals
Whether you are a physician, pharmacist, or any other member of the healthcare profession, this website is dedicated to presenting you the GSK Antigen-Specific Cancer Immunotherapeutics (ASCI) approach. The basis of this approach to cancer immunotherapy is to educate the patient's own immune system to fight cancer.
The ASCI website provides tools such as e-learning realized in collaboration with scientific specialists. We encourage you to explore the website as a whole and learn more about GSK's ASCI approach.
If you are a professional,
click here to discover
Working for us
Patient website
The patient website is dedicated to help patients, their family and friends up-to-date about this current cancer immunotherapeutic approach in an easy-to-understand format. Users will find information about cancer, cancer immunotherapy, ASCI treatment, ASCI in the treatment of Lung Cancer and clinical studies. A glossary is available so patients can quickly learn the meanings of unfamiliar medical terms.
Visit Patient websiteMAGRIT and DERMA trials
The Ascitrials website gives information about the MAGRIT and DERMA clinical studies, including the criteria necessary for patients to participate.
MAGRIT is a large scale, worldwide Phase III study investigating efficacy and safety of MAGE-A3 ASCI in the treatment of Non Small Cell Lung Cancer. GSK targets the recruitment of about 2300 patients in this randomized, double-blind, placebo-controlled trial.
DERMA is a large, international Phase III study looking at the efficacy and safety of MAGE-A3 ASCI in the treatment of melanoma. The aim is to recruit 1300 patients.
© 2001 - 2008 GlaxoSmithKline plc. All rights reserved.